NVCT

Nuvectis Pharma Inc

NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY

$20.10

-6.94% today

Updated 2026-08-04

Market cap

$624.84M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.33

Dividend yield

—

52W range

$6 – $29

Volume

0.3M

Market cap

$624.84M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.33

Dividend yield

—

52W range

$6 – $29

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.5

Quality

C+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →207 stocks currently score above 75

Price targets

Analyst target

$31.80

+58.21%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-6.51M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$149000.00	$0.00	$0.00	$0.00	$0.00
Net income	$-18.79M	$-22.26M	$-19.00M	$-26.44M	$-6.05M
EPS	—	—	—	—	$-1.33
Free cash flow	$-13.56M	$-15.95M	$-12.25M	$-16.01M	$-6.51M
Profit margin	-12,608.72%	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-06-30	MOSSERI, MARLIO CHARLES	Buy	50,000	$18.32
2026-06-30	BENTSUR, RON	Buy	12,500	$20.00
2026-06-11	SANCHEZ, JUAN	Buy	35,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NVCT	$624.84M	17	4.3	3.0	5.0	5.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Nuvectis Pharma Inc trades at $20.10. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Nuvectis Pharma Inc's stock price?

Nuvectis Pharma Inc (NVCT) trades at $20.10.

Is Nuvectis Pharma Inc overvalued?

Nuvectis Pharma Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Nuvectis Pharma Inc (NVCT)?

The 12-month analyst consensus target is $31.80, about 58.2% above the current $20.10. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-191.00%

Beta-0.25

50D MA$15.51

200D MA$9.80

Shares out0.03B

Float0.02B

Short ratio—

Avg volume0.3M

Performance

1 week+10.13%

1 month+9.96%

3 months+142.07%

YTD+185.03%

1 year—

3 years—

5 years—

Compare

NVCT vs LLY →NVCT vs JNJ →NVCT vs ABBV →Stock screener →